- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Alan Menter Discusses 2022 Psoriasis Guideline Updates
Alan Menter, MD, chairman of dermatology, Baylor University Medical Center, discussed some of the updated psoriasis guidelines at the 2022 American Academy of Dermatology Annual Meeting.
Alan Menter, MD, chairman of dermatology, Baylor University Medical Center, discussed some of the updated psoriasis guidelines at the 2022 American Academy of Dermatology Annual Meeting.
Transcript
What are some of the updated psoriasis guidelines and recommendations for 2022, in relation to cardiovascular comorbidities?
The old theory that coronary artery disease is just caused by cholesterol is no longer true; it's caused by inflammation. Inflammation in the coronary artery is very similar to the inflammation in psoriasis, so improving the skin, we do believe, will improve coronary artery disease.
I chaired—co-chaired, there was 2 of us who chaired—the guidelines that we published in 2019 and 2020 in JAAD [Joint American Academy of Dermatology], and we had 6 papers, all of which were about 70 pages long. One of the guidelines related to coronary artery disease. We are relatively up to date with the fact that coronary artery disease is now inflammation driven, very similar inflammation to psoriasis, and not just driven by cholesterol.
Infertility Coverage Boosts ART Use and Pregnancy Success: Richard A. Brook, MS, MBA
August 26th 2025In this episode, Richard A. Brook, MS, MBA, discusses his study showing that infertility treatment coverage increases assisted reproductive technology (ART) use and improves pregnancy outcomes.
Listen
Current and Emerging Options for Uncommon EGFR- and Exon 20 Insertion–Mutated NSCLC
September 8th 2025Uncommon EGFR mutations in non–small cell lung cancer (NSCLC) remain challenging to treat, but new tyrosine kinase inhibitors, bispecific antibodies, and a proposed “PACCage insert” framework provide opportunities to advance precision therapy.
Read More
Clinical Advances in EGFR-Mutated NSCLC: Insights From MARIPOSA and FLAURA2
September 7th 2025Treatment of EGFR-mutated non–small cell lung cancer (NSCLC) is shifting toward next-generation sequencing and combination regimens that improve survival but increase toxicity, requiring individualized care.
Read More
